Control of alternative splicing in immune responses: Many regulators, many predictions, much still to learn

Immunological Reviews

Volumn 253, Issue 1, 2013, Pages 216-236

  Martinez, Nicole M ^a   Lynch, Kristen W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alternative splicing; Gene regulation; mRNA profiling; Splicing factors; T cell response

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CD28 ANTIGEN; CD3 ANTIGEN; CD3 XI ANTIGEN; CD3 ZETA ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CD6 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CELF2 PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; FIPILI PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; HRB PROTEIN; INITIATION FACTOR 4G2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; INTERLEUKIN 7 RECEPTOR ALPHA; LUC7L PROTEIN; PROTEIN; RBM25 PROTEIN; SEC16A PROTEIN; SNRPB PROTEIN; TIR8 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALTERNATIVE RNA SPLICING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EXON; GENE CONTROL; HUMAN; IMMUNE RESPONSE; MOLECULAR MECHANICS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; REVIEW; RNA BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ALTERNATIVE SPLICING; ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MAMMALS; RNA-BINDING PROTEINS; T-LYMPHOCYTES; TRANSCRIPTOME;

EID: 84875798204     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12047     Document Type: Review

References (134)

1. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619.
2. Wang ET, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008;456:470-476.
3. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science 2008;320:1643-1647.
4. Moore MJ, Proudfoot NJ. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 2009;136:688-700.
5. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008;40:1413-1415.
6. Martinez NM, et al. Alternative splicing networks regulated by signaling in human T cells. RNA 2012;18:1029-1040.
7. Grigoryev YA, et al. Genome-wide analysis of immune activation in human T and B cells reveals distinct classes of alternatively spliced genes. PLoS ONE 2009;4:e7906.
8. Ip JY, Tong A, Pan Q, Topp JD, Blencowe BJ, Lynch KW. Global analysis of alternative splicing during T-cell activation. RNA 2007;13:563-572.
9. Lynch KW. Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol 2004;4:931-940.
10. Moulton VR, Tsokos GC. Alternative splicing factor/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex. J Biol Chem 2010;285:12490-12496.
11. Tsuzaka K, et al. TCR zeta mRNA with an alternatively spliced 3'-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR zeta and TCR/CD3 complex. J Immunol 2003;171:2496-2503.
12. Nambiar MP, et al. Polymorphisms/mutations of TCR-zeta-chain promoter and 3' untranslated region and selective expression of TCR zeta-chain with an alternatively spliced 3' untranslated region in patients with systemic lupus erythematosus. J Autoimmun 2001;16:133-142.
13. Chowdhury B, et al. Stability and translation of TCR zeta mRNA are regulated by the adenosine-uridine-rich elements in splice-deleted 3' untranslated region of zeta-chain. J Immunol 2006;177:8248-8257.
14. Chowdhury B, et al. Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3'-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem 2005;280:18959-18966.
15. Nambiar MP, et al. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1948-1955.
16. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003;21:107-137.
17. Lynch KW, Weiss A. A model system for the activation-induced alternative-splicing of CD45 implicates protein kinase C and Ras. Mol Cell Biol 2000;20:70-80.
18. Dornan S, et al. Differential association of CD45 isoforms with CD4 and CD8 regulates the actions of specific pools of p56lck tyrosine kinase in T cell antigen receptor signal transduction. J Biol Chem 2002;277:1912-1918.
19. Xu Z, Weiss A. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 2002;3:764-771.
20. Lynch KW, Weiss A. A CD45 polymorphism associated with Muliple Sclerosis disrupts an exonic splicng silencer. J Biol Chem 2001;276:24341-24347.
21. Zilch CF, Walker AM, Timon M, Goff LK, Wallace DL, Beverley PCL. A point mutation within CD45 exon A is the cause of variant CD45RA splicing in humans. Eur J Immunol 1998;28:22-29.
22. Tchilian EZ, et al. A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. AIDS 2001;15:1892-1894.
23. Jacobsen M, et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 2000;26:495-499.
24. Imbeault M, Giguere K, Ouellet M, Tremblay MJ. Exon level transcriptomic profiling of HIV-1-infected CD4(+) T cells reveals virus-induced genes and host environment favorable for viral replication. PLoS Pathog 2012;8:e1002861.
25. Goodwin RG, et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990;60:941-951.
26. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007;7:144-154.
27. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-432.
28. Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 2003;198:1797-1806.
29. Rose T, Lambotte O, Pallier C, Delfraissy JF, Colle JH. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol 2009;182:7389-7397.
30. Gregory SG, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39:1083-1091.
31. McKay FC, et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes Immun 2008;9:1-6.
32. Vudattu NK, Magalhaes I, Hoehn H, Pan D, Maeurer MJ. Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun 2009;10:132-140.
33. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990-8000.
34. Cooke MP, Perlmutter RM. Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol 1989;1:66-74.
35. Brignatz C, et al. Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Mol Cell Biol 2009;29:6438-6448.
36. Davidson D, Chow LM, Fournel M, Veillette A. Differential regulation of T cell antigen responsiveness by isoforms of the src-related tyrosine protein kinase p59fyn. The J Exp Med 1992;175:1483-1492.
37. Davidson D, Viallet J, Veillette A. Unique catalytic properties dictate the enhanced function of p59fynT, the hemopoietic cell-specific isoform of the Fyn tyrosine protein kinase, in T cells. Mol Cell Biol 1994;14:4554-4564.
38. Weil R, et al. Altered expression of tyrosine kinases of the Src and Syk families in human T-cell leukemia virus type 1-infected T-cell lines. J Virol 1999;73:3709-3717.
39. Rothrock C, Cannon B, Hahm B, Lynch KW. A conserved signal-responsive sequence mediates activation-induced alternative splicing of CD45. Mol Cell 2003;12:1317-1324.
40. Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol 2007;176:929-939.
41. van Genderen C, et al. Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 1994;8:2691-2703.
42. Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. Oncogene 2006;25:7492-7504.
43. Travis A, Amsterdam A, Belanger C, Grosschedl R. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. Genes Dev 1991;5:880-894.
44. Waterman ML, Fischer WH, Jones KA. A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev 1991;5:656-669.
45. Mallory MJ, Jackson J, Weber B, Chi A, Heyd F, Lynch KW. Signal- and development-dependent alternative splicing of LEF1 in T cells is controlled by CELF2. Mol Cell Biol 2011;31:2184-2195.
46. Leiden JM, Thompson CB. Transcriptional regulation of T-cell genes during T-cell development. Curr Opin Immunol 1994;6:231-237.
47. Dembowski JA, Grabowski PJ. The CUGBP2 splicing factor regulates an ensemble of branchpoints from perimeter binding sites with implications for autoregulation. PLoS Genet 2009;5:e1000595.
48. Izquierdo JM, Valcárcel J. Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR proteins to regulate Fas alternative splicing. J Biol Chem 2007;282:1539-1543.
49. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009;136:777-793.
50. Licatalosi DD, Darnell RB. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet 2010;11:75-87.
51. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010;463:457-463.
52. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006;210:171-186.
53. Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009;136:701-718.
54. House AE, Lynch KW. Regulation of Alternative Splicing: more than just the ABCs. J Biol Chem 2008;283:1217-1221.
55. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev 2009;10:741-754.
56. Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J 2009;417:15-27.
57. Martinez-Contreras R, Cloutier P, Shkreta L, Fisette J-F, Revil T, Chabot B. hnRNP Proteins and Splicing Control. Austin: Landes Biosciences, 2007.
58. Motta-Mena LB, Heyd F, Lynch KW. Context-dependent regulatory mechanism of the splicing factor hnRNP L. Mol Cell 2010;29:223-234.
59. Heyd F, Lynch KW. Degrade, move, regroup: signaling control of splicing proteins. Trends Biochem Sci 2011;36:397-404.
60. Mayya V, et al. Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2009;2:ra46.
61. Tong A, Nguyen J, Lynch KW. Differential expression of CD45 isoforms is controlled by the combined activity of basal and inducible splicing-regulatory elements in each of the variable exons. J Biol Chem 2005;280:38297-38304.
62. Rothrock CR, House AE, Lynch KW. HnRNP L represses exon splicing via a regulated exonic splicing silencer. EMBO J 2005;24:2792-2802.
63. Melton AA, Jackson J, Wang J, Lynch KW. Combinatorial control of signal-induced exon repression by hnRNP L and PSF. Mol Cell Biol 2007;27:6972-6984.
64. Topp JD, Jackson J, Melton AA, Lynch KW. A cell-based screen for splicing regulators identifies hnRNP LL as a distinct signal-induced repressor of CD45 variable exon 4. RNA 2008;14:2038-2049.
65. Gaudreau MC, Heyd F, Bastien R, Wilhelm B, Moroy T. Alternative splicing controlled by heterogeneous nuclear ribonucleoprotein L regulates development, proliferation, and migration of thymic pre-T cells. J Immunol 2012;188:5377-5388.
66. Hui J, et al. Intronic CA-repeat and CA-rich elements: a new class of regulators of mammalian alternative splicing. EMBO J 2005;24:1988-1998.
67. Hung LH, Heiner M, Hui J, Schreiner S, Benes V, Bindereif A. Diverse roles of hnRNP L in mammalian mRNA processing: a combined microarray and RNAi analysis. RNA 2008;14:284-296.
68. Hui J, Stangl K, Lane WS, Bindereif A. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol 2003;10:33-37.
69. Liu G, et al. A conserved serine of heterogeneous nuclear ribonucleoprotein L (hnRNP L) mediates depolarization-regulated alternative splicing of potassium channels. J Biol Chem 2012;287:22709-22716.
70. Wu Z, et al. Memory T cell RNA rearrangement programmed by heterogeneous nuclear ribonucleoprotein hnRNPLL. Immunity 2008;29:863-875.
71. Oberdoerffer S, Moita LF, Neems D, Freitas RP, Hacohen N, Rao A. Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL. Science 2008;321:686-691.
72. Levinson N, et al. Use of transcriptional synergy to augment sensitivity of a splicing reporter assay. RNA 2006;12:925-930.
73. Wu Z, Yates AL, Hoyne GF, Goodnow CC. Consequences of increased CD45RA and RC isoforms for TCR signaling and peripheral T cell deficiency resulting from heterogeneous nuclear ribonucleoprotein L-like mutation. J Immunol 2002;185:231-238.
74. Heyd F, Lynch KW. Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing. Mol Cell 2010;40:126-137.
75. Shav-Tal Y, Zipori D. PSF and p54(nrb)/NonO-multi-functional nuclear proteins. FEBS Lett 2002;531:109-114.
76. Heyd F, Lynch KW. PSF controls expression of histone variants and cellular viability in thymocytes. Biochem Biophys Res Commun 2011;414:743-749.
77. Dasgupta T, Ladd AN. The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. Wiley Interdiscip Rev RNA 2011;3:104-121.
78. Faustino NA, Cooper TA. Identification of putative new splicing targets for ETR-3 using sequences identified by systematic evolution of ligands by exponential enrichment. Mol Cell Biol 2005;25:879-887.
79. Beisang D, Rattenbacher B, Vlasova-St Louis IA, Bohjanen PR. Regulation of CUG-binding protein 1 (CUGBP1) binding to target transcripts upon T cell activation. J Biol Chem 2012;287:950-960.
80. Anderson P, et al. A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol 1990;144:574-582.
81. Puig O, Gottschalk A, Fabrizio P, Seraphin B. Interaction of the U1 snRNP with nonconserved intronic sequences affects 5' splice site selection. Genes Dev 1999;13:569-580.
82. Forch P, et al. The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. Mol Cell 2000;6:1089-1098.
83. Gottschalk A, et al. A comprehensive biochemical and genetic analysis of the yeast U1 snRNP reveals five novel proteins. RNA 1998;4:374-393.
84. Piecyk M, et al. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J 2000;19:4154-4163.
85. Del Gatto-Konczak F, et al. The RNA-binding protein TIA-1 is a novel mammalian splicing regulator acting through intron sequences adjacent to a 5' splice site. Mol Cell Biol 2000;20:6287-6299.
86. Liu C, Cheng J, Mountz JD. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J 1995;310:957-963.
87. Cheng J, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
88. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995;154:2706-2713.
89. Izquierdo JM, et al. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell 2005;19:475-484.
90. Tian Q, Taupin J, Elledge S, Robertson M, Anderson P. Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 1995;182:865-874.
91. Dember LM, Kim ND, Liu KQ, Anderson P. Individual RNA recognition motifs of TIA-1 and TIAR have different RNA binding specificities. J Biol Chem 1996;271:2783-2788.
92. Aznarez I, et al. A systematic analysis of intronic sequences downstream of 5' splice sites reveals a widespread role for U-rich motifs and TIA1/TIAL1 proteins in alternative splicing regulation. Genome Res 2008;18:1247-1258.
93. Wang Z, et al. iCLIP predicts the dual splicing effects of TIA-RNA interactions. PLoS Biol 2010;8:e1000530.
94. ten Dam GB, et al. Regulation of alternative splicing of CD45 by antagonistic effects of SR protein splicing factors. J Immunol 2000;164:5287-5295.
95. Wang H-Y, Xu X, Ding J-H, Bermingham JR, Fu X-D. SC35 plays a role in T cell development and alternative splicing of CD45. Mol Cell 2001;7:331-342.
96. Screaton GR, et al. Identification and characterization of three members of the human SR family of pre-mRNA splicing factors. EMBO J 1995;14:4336-4349.
97. Lukong KE, Richard S. Sam68, the KH domain-containing superSTAR. Biochim Biophys Acta 2003;1653:73-86.
98. Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002;420:691-695.
99. Arch R, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992;257:682-685.
100. Konig H, Ponta H, Herrlich P. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J 1998;17:2904-2913.
101. Weg-Remers S, Ponta H, Herrlich P, Konig H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J 2001;20:4194-4203.
102. Cheng C, Yaffe MB, Sharp PA. A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 2006;20:1715-1720.
103. Batsche E, Yaniv M, Muchardt C. The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struc Mol Biol 2006;13:22-29.
104. Kornblihtt AR. Chromatin, transcript elongation and alternative splicing. Nat Struc Mol Biol 2006;13:5-7.
105. Shukla S, et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 2011;479:74-79.
106. Singh P, Lee DH, Szabo PE. More than insulator: multiple roles of CTCF at the H19-Igf2 imprinted domain. Front Genet 2012;3:214.
107. Preussner M, et al. HnRNP L and L-like cooperate in multiple-exon regulation of CD45 alternative splicing. Nucleic Acids Res 2012;40:5666-5678.
108. Motta-Mena LB, Smith SA, Mallory MJ, Jackson J, Wang J, Lynch KW. A disease-associated polymorphism alters splicing of the human CD45 phosphatase gene by disrupting combinatorial repression by heterogeneous nuclear ribonucleoproteins (hnRNPs). J Biol Chem 2011;286:20043-20053.
109. Ray P, Kar A, Fushimi K, Havlioglu N, Chen X, Wu JY. PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10. J Mol Neurosci 2011;45:453-466.
110. Kim KK, Kim YC, Adelstein RS, Kawamoto S. Fox-3 and PSF interact to activate neural cell-specific alternative splicing. Nucleic Acids Res 2011;39:3064-3078.
111. Ladd AN, Taffet G, Hartley C, Kearney DL, Cooper TA. Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy. Mol Cell Biol 2005;25:6267-6278.
112. Huot ME, et al. The Sam68 STAR RNA-binding protein regulates mTOR alternative splicing during adipogenesis. Mol Cell 2012;46:187-199.
113. Iijima T, et al. SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1. Cell 2011;147:1601-1614.
114. Xu X, et al. ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. Cell 2005;120:59-72.
115. Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 2006;15:2490-2508.
116. Atkinson TP, Hall CG, Goldsmith J, Kirkham PM. Splice variant in TCRzeta links T cell receptor signaling to a G-protein-related signaling pathway. Biochem Biophys Res Commun 2003;310:761-766.
117. Magistrelli G, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999;29:3596-3602.
118. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 2006;116:3252-3257.
119. Castro MA, et al. Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse. J Immunol 2007;178:4351-4361.
120. Thakral D, Dobbins J, Devine L, Kavathas PB. Differential expression of the human CD8beta splice variants and regulation of the M-2 isoform by ubiquitination. J Immunol 2008;180:7431-7442.
121. Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol 2005;174:6672-6676.
122. Meyer D, et al. CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains. J Biol Chem 2009;284:2235-2244.
123. King PD, Sandberg ET, Selvakumar A, Fang P, Beaudet AL, Dupont B. Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing. J Immunol 1995;154:6080-6093.
124. Wang Y, Su X, Sorenson CM, Sheibani N. Modulation of PECAM-1 expression and alternative splicing during differentiation and activation of hematopoietic cells. J Cell Biochem 2003;88:1012-1024.
125. Alms WJ, Atamas SP, Yurovsky VV, White B. Generation of a variant of human interleukin-4 by alternative splicing. Mol Immunol 1996;33:361-370.
126. Kaur G, Goodall JC, Jarvis LB, Hill Gaston JS. Characterisation of Foxp3 splice variants in human CD4+ and CD8+ T cells-identification of Foxp3Delta7 in human regulatory T cells. Mol Immunol 2010;48:321-332.
127. Whistler T, Chiang CF, Lonergan W, Hollier M, Unger ER. Implementation of exon arrays: alternative splicing during T-cell proliferation as determined by whole genome analysis. BMC Genomics 2010;11:496.
128. Alcaraz-Garcia MJ, et al. Human and mouse DOCK10 splicing isoforms with alternative first coding exon usage are differentially expressed in T and B lymphocytes. Hum Immunol 2011;72:531-537.
129. Jia Z, et al. A novel splice variant of FR4 predominantly expressed in CD4+CD25+ regulatory T cells. Immunol Invest 2009;38:718-729.
130. Birzele F, et al. Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human. Nucleic Acids Res 2011;39:7946-7960.
131. Jensen LE, Whitehead AS. IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability. J Biol Chem 2001;276:29037.
132. Ohya S, Fujimori T, Kimura T, Yamamura H, Imaizumi Y. Novel spliced variants of large-conductance Ca(2+)-activated K(+)-channel beta2-subunit in human and rodent pancreas. J Pharmacol Sci 2010;114:198-205.
133. Syken J, Macian F, Agarwal S, Rao A, Munger K. TID1, a mammalian homologue of the drosophila tumor suppressor lethal(2) tumorous imaginal discs, regulates activation-induced cell death in Th2 cells. Oncogene 2003;22:4636-4641.
134. Jalink M, Ge Z, Liu C, Bjorkholm M, Gruber A, Xu D. Human normal T lymphocytes and lymphoid cell lines do express alternative splicing variants of human telomerase reverse transcriptase (hTERT) mRNA. Biochem Biophys Res Commun 2007;353:999-1003.